Johannes G. C. P. Schikan
Gründer bei PHARVARIS N.V.
Vermögen: 10 Mio $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Johannes G. C. P. Schikan
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.
220
| Non-Profit Organization | Miscellaneous Commercial Services | 220 |
| Public Company | Pharmaceuticals: Major | 56 | |
| Public Company | Pharmaceuticals: Major | 25 | |
| Public Company | Pharmaceuticals: Major | 22 | |
| Extinct | Pharmaceuticals: Major | 20 | |
| Extinct | Biotechnology | 14 | |
| Public Company | Pharmaceuticals: Major | 14 | |
| Subsidiary | Pharmaceuticals: Major | 12 | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.
10
| Holding Company | Biotechnology | 10 |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Microbiotica Ltd.
 Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom.
8
| Holding Company | Biotechnology | 8 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland.
8
| Subsidiary | Biotechnology | 8 |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.
3
| Extinct | Biotechnology | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Johannes G. C. P. Schikan
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Operating Officer Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal Director of Finance/CFO | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin Graduate Degree Graduate Degree Graduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Public Communications Contact Corporate Officer/Principal Corporate Officer/Principal | |
| UCB | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
The Biotechnology Institute
 The Biotechnology Institute Miscellaneous Commercial ServicesCommercial Services The Biotechnology Institute is a non-profit organization, which engages in designing and managing programs about biotechnology research. Its programs include BioGENEius Challenges, leadership awards, and Adopt-A-School. The company was founded in 1998 and is headquartered in Washington, DC. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Medical School | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Chairman | |
| IMMUNOGEN, INC. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
| RHYTHM PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member | |
| Stanford University | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| University of Gothenburg | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Founder | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree Masters Business Admin | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PASSAGE BIO, INC. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Chief Operating Officer Chief Tech/Sci/R&D Officer Chief Executive Officer | |
| SEAGEN INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
| University of Lund | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
Avillion LLP
 Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | President President Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | General Counsel Corporate Officer/Principal Sales & Marketing | |
| GILEAD SCIENCES, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal Sales & Marketing | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
| University of Michigan | College/University | Undergraduate Degree Undergraduate Degree | |
| LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder General Counsel | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
| ALKERMES PLC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Longwood Fund Management LLC
 Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Detwiler and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Consultant / Advisor | |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| ATRECA, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| ARCA BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member President | |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | President Corporate Officer/Principal |
Statistik
International
| Vereinigte Staaten | 32 |
| Dänemark | 5 |
| Schweden | 5 |
| Schweiz | 4 |
| Vereinigtes Königreich | 3 |
Sektoral
| Health Technology | 36 |
| Consumer Services | 12 |
| Commercial Services | 2 |
| Finance | 2 |
Operativ
| Director/Board Member | 749 |
| Corporate Officer/Principal | 256 |
| Independent Dir/Board Member | 210 |
| Chairman | 164 |
| Chief Executive Officer | 153 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Jean-Francois Formela | 48 |
| David Mott | 45 |
| Stephen P. Squinto | 40 |
| Thomas Woiwode | 39 |
| John Maraganore | 38 |
| Flemming Ørnskov | 34 |
| Jacob Uno Stanley Gunterberg | 33 |
| Martijn Kleijwegt | 33 |
| Ted Love | 31 |
| N. Coles | 30 |
| Rémi Droller | 29 |
| Steven Holtzman | 28 |
| David Pyott | 27 |
| David Stack | 27 |
| James Sapirstein | 26 |
- Börse
- Insiders
- Johannes G. C. P. Schikan
- Unternehmensverbindungen